非酒精性脂肪性肝病患者估算的肾小球滤过率的变化及其影响因素分析*

doi:10.3969/j.issn.1672-5069.2017.02.010

实用肝脏病杂志 ›› 2017, Vol. 20 ›› Issue (2): 165-170.doi: 10.3969/j.issn.1672-5069.2017.02.010

非酒精性脂肪性肝病患者估算的肾小球滤过率的变化及其影响因素分析*

孙长贵，曾静，孙婉璐，陈光榆，潘勤，范建高

215300 江苏省昆山市老年医院（孙长贵）；上海交通大学医学院附属新华医院消化内科（曾静，孙婉璐，陈光榆，潘勤，范建高）

收稿日期:2016-09-28 出版日期:2017-04-10 发布日期:2017-06-07
通讯作者: 曾静，女，26 岁，医学博士，住院医师。E-mail：littleangel01@126.com
作者简介:孙长贵，男，50岁，副主任医师。主要从事消化系统疾病的诊治研究。E-mail: changguis@163.com
基金资助:
国家科技部 973 课题（编号：2012CB517501）

Changes of estimated glomerular filtration rates in healthy check-up adults with nonalcoholic fatty liver diseases

Sun Changgui， Zeng Jing，Sun Wanlu，et al.

Geriatric Hospital，Kunshan 215300，Jiangsu Province， China；Department of Gastroenterology，Center for Fatty Liver Disease Study，Xinhua Hospital，Affiliated to Shanghai Jiaotong University School of Medicine，Shanghai 200092 China

Received:2016-09-28 Online:2017-04-10 Published:2017-06-07

摘要/Abstract

摘要： 目的探讨健康体检成人脂肪肝和肾小球滤过率估算值（eGFR）水平减低发生率及其影响因素。方法对600例机关职员进行年度健康体检，使用B超检查诊断脂肪肝，使用瞬时弹性检测仪测定肝脏受控衰减参数（CAP），常规进行血生化检查并计算eGFR。结果在符合纳入标准的292例成人中，B超证实非酒精性脂肪性肝病（NAFLD）患者154例（52.7%）；与138例无脂肪肝组比，NAFLD组体质指数、腰围、血红蛋白、AST、ALT、碱性磷酸酶、谷氨酰转肽酶、白蛋白、甘油三酯、尿酸和CAP等指标显著增高，而eGFR（107.95±35.38 mL.min-1. per 1.73 m2对122.95±66.19 mL.min-1. per 1.73 m2）则显著降低（P<0.05）；在292例研究对象中，eGFR与CAP值呈负相关（r=-0.137，P=0.020），并且eGFR随着CAP值的增高而降低（P<0.05）；多因素Logistic回归分析提示性别、年龄、肌酐、CAP值是影响受检者肾功能的独立影响因素。结论 B超诊断的NAFLD患者存在亚临床型肾脏功能减退，肝脏脂肪含量增多与健康体检成人eGFR下降密切相关。因此，对NAFLD患者，需预防慢性肾病的发生。

关键词: 非酒精性脂肪性肝病, 受控衰减参数, 肾小球滤过率估算值

Abstract: Objective To explore the changes of estimated glomerular filtration rates（eGFR） in healthy check-up adults with nonalcoholic fatty liver diseases（NAFLD）.Methods Six hundred individuals underwent routine check-up，and 292 without history of alcohol consumption，liver diseases and kidney diseases were enrolled in this study. Nonalcoholic fatty liver disease was diagnosed by B-mode ultrasound. Controlled attenuation parameter（CAP） was measured by FibroScan and blood biochemistry tests were routinely assayed. The eGFR was calculated.Results A total of 154 patients（52.7%） were found to have NAFLD out of 292 participants. The body mass index，waist circumference，blood haemoglobin，alanine aminotransferase，aspartate aminotransferase，gamma-glutamyltransferase，urea acid，and triglyceride were significantly increased in the NAFLD group as compared to 138 controls without NAFLD；eGFR in the NAFLD group was significantly lower than that in the control group [（107.95±35.38 mL.min-1. per 1.73 m2 vs. 122.95 66.19 mL.min-1. per 1.73 m2，P<0.05]；The eGFR was negatively correlated with CAP （r=-0.137，P=0.137），and the eGFR was decreased sharply with increased CAP value in this 292 check-up individuals；There was no significant difference as respect to gender，age，blood urea nitrogen， serum creatinine levels between groups of NAFLD and control；The multivariate Logistic regression analysis showed that gender，age，serum creatinine levels and CAP were independent factors for renal damage in patients with NAFLD.Conclusion The findings in our study suggest that mild renal function reduction presenting with decreased eGFR exists in patients with NAFLD. Therefore，prevention of chronic kidney disease is necessary in patients with NAFLD.

Key words: Nonalcoholic fatty liver diseases, Controlled attenuation parameter, Estimated glomerular filtration rates

孙长贵，曾静，孙婉璐，陈光榆，潘勤，范建高. 非酒精性脂肪性肝病患者估算的肾小球滤过率的变化及其影响因素分析*[J]. 实用肝脏病杂志, 2017, 20(2): 165-170.

Sun Changgui， Zeng Jing，Sun Wanlu，et al.. Changes of estimated glomerular filtration rates in healthy check-up adults with nonalcoholic fatty liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(2): 165-170.

参考文献

[1] Levey AS，Bosch JP，Lewis JB，et al. A more accurate method to estimate glomerular filtration rate from serum creatinine:a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med，1999，130（6）:461-470．
[2] Singal AK，Salameh H，Kuo YF，et al. Evolving frequency and outcomes of simultaneous liver kidney transplants based on liver disease etiology. Transplantation，2014，98（2）:216-221.
[3] Allen AM，Kim WR，Therneau TM，et al. Chronic kidney disease and associated mortality after liver transplantation--a time-dependent analysis using measured glomerular filtration rate. J Hepatol，2014，61（2）:286-292.
[4] Chang Y，Ryu S，Sung E，et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism，2008，57（4）:569-576.
[5] Ryu S，Chang Y，Kim DI，et al. Gamma-glutamyltransferase as a predictor of chronic kidney disease in nonhypertensive and nondiabetic Korean men. Clin Chem，2007，53（1）:71-77.
[6] Targher G，Bertolini L，Rodella S，et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia，2008，51（3）:444-450.
[7] Johns BR，Pao AC，Kim SH. Metabolic syndrome， insulin resistance and kidney function in non-diabetic individuals. Nephrol Dial Transplant，2012，27（4）:1410-1415.
[8] Ferraro PM，Lupo A，Yabarek T，et al. Metabolic syndrome，cardiovascular disease，and risk for chronic kidney disease in an Italian cohort:analysis of the INCIPE study. Metab Syndr Relat Disord，2011，9（5）:381-388.
[9] Li G，Shi W，Hug H，et al. Nonalcoholic fatty liver disease associated with impairment of kidney function in nondiabetes population. Biochem Med （Zagreb），2012，22（1）:92-99.
[10] 信丰智，范建高. 欧洲非酒精性脂肪性肝病诊疗指南简介. 实用肝脏病杂志，2016，19（4）:Ⅶ-Ⅷ.
[11] 袁平戈. 瞬时弹性成像技术在肝病诊断中的应用进展. 实用肝脏病杂志，2016，19（1）:4-7.
[12] 沈峰，徐正婕，潘勤，等. FibroScan实施受控衰减参数评价脂肪肝的影响因素及重复性分析. 实用肝脏病杂志，2013，16（1）:59-62.
[13] 曾民德. 非酒精性脂肪性肝病:回顾历史，展望未来. 实用肝脏病杂志，2016，19（2）:129-131.

[1]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[2]	李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851.
[3]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[4]	张胥磊, 杨庆余, 韩秋玉, 缪鋆鋆, 蔡仁诚, 马亦旻. 自拟中药治疗非酒精性脂肪性肝病患者血清炎症反应指标水平的变化*[J]. 实用肝脏病杂志, 2019, 22(5): 660-663.
[5]	张兰华, 邵琴, 夏振娟. 非酒精性脂肪性肝病儿童血清25-（OH）D3和IL-17水平变化初步研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 522-525.
[6]	谢晓, 刘婷, 董志霞, 夏幼辰, 张启迪, 曲颖, 蔡晓波, 徐铭益, 陆伦根. FibroTouch检测肝脏受控衰减参数对肝脂肪变的诊断价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 526-529.
[7]	符亮, 吴冬冰, 纪新尊, 万鸿兴, 李文刚, 饶卉明, 钟静, 江婷婷. 超声定量评估非酒精性脂肪性肝病患者肝脏ARFI值对显著NASH的诊断价值分析[J]. 实用肝脏病杂志, 2019, 22(3): 377-380.
[8]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[9]	霍会芹,巩晓红,李正宏. 采用实时三维超声和斑点追踪技术评价非酒精性脂肪性肝病肝硬化患者右心功能^*[J]. 实用肝脏病杂志, 2019, 22(2): 244-247.
[10]	苏淑婷,钟燕（综述）,宓余强（审校）. 非酒精性脂肪性肝病分级分期管理研究进展[J]. 实用肝脏病杂志, 2019, 22(2): 293-296.
[11]	谢晓（综述）,陆伦根（审校）. 无创诊断和评估非酒精性脂肪性肝炎研究进展^*[J]. 实用肝脏病杂志, 2019, 22(2): 301-306.
[12]	张枫, 阎妍. 非酒精性脂肪性肝病患者血清载脂蛋白B水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(1): 61-64.
[13]	宋娜, 刘晓燕, 刘畅, 山秀杰, 苏东峰, 李丽慧. 非酒精性脂肪性肝病合并2型糖尿病患者血浆促甲状腺激素水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(1): 65-68.
[14]	崔清华, 陶红, 王晓玥, 张凤丽. 非酒精性脂肪性肝病患者血清糖化血红蛋白水平和心功能指标的变化研究^*[J]. 实用肝脏病杂志, 2019, 22(1): 69-72.
[15]	钟燕, 苏淑婷综述, 宓余强审校. 非酒精性脂肪性肝病治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(1): 145-148.

非酒精性脂肪性肝病患者估算的肾小球滤过率的变化及其影响因素分析*

Changes of estimated glomerular filtration rates in healthy check-up adults with nonalcoholic fatty liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价